跳至主要内容
临床试验/NCT07622212
NCT07622212招募中不适用

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)

RenJi Hospital1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2024年1月1日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
180
试验地点
1

研究概览

简要总结

A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

详细描述

Acute deep venous thrombosis (DVT) is associated with development of post-thrombotic syndrome (PTS). Early removal of iliofemoral thrombosis by percutaneous mechanical thrombectomy (PMT) may reduce the incidence of PTS. There is currently a lack of research on which device is optimal for thrombus removal. The aim of this study is to conduct a multicenter, observational, prospective cohort study in patients with acute iliofemoral deep vein thrombosis (DVT), performing a head-to-head comparison of two different types of mechanical thrombectomy devices - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged between 18 and 85 years;
  • Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;
  • Time from symptom onset to endovascular treatment ≤ 14 days;
  • Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;
  • Patients sign the informed consent form.

排除标准

  • Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;
  • Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
  • Known allergy to heparin, low molecular weight heparin, contrast agents, etc.
  • Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.
  • Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.
  • Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
  • Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.
  • Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or platelet count < 80,000/mL;
  • History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
  • Pregnant women;
  • Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy < 24 months
  • Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;
  • Patients unwilling to participate in this trial.

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验